{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:11:56Z","timestamp":1788912716193,"version":"build-2803163510"},"reference-count":160,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s12035-024-04143-2","type":"journal-article","created":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T10:01:43Z","timestamp":1713520903000},"page":"9416-9431","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Application of CRISPR\/Cas9 System in the Treatment of Alzheimer\u2019s Disease and Neurodegenerative Diseases"],"prefix":"10.1007","volume":"61","author":[{"given":"Araz","family":"Rahimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parsa","family":"Sameei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Mousavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimia","family":"Ghaderi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Hassani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepideh","family":"Hassani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2202-9598","authenticated-orcid":false,"given":"Shahriar","family":"Alipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,19]]},"reference":[{"issue":"5","key":"4143_CR1","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1242\/dmm.030205","volume":"10","author":"AD Gitler","year":"2017","unstructured":"Gitler AD, Dhillon P, Shorter J (2017) Neurodegenerative disease: models, mechanisms, and new hope. Dis Model Mech 10(5):499\u2013502","journal-title":"Dis Model Mech"},{"key":"4143_CR2","first-page":"407","volume":"163","author":"H Checkoway","year":"2011","unstructured":"Checkoway H, Lundin JI, Kelada SN (2011) Neurodegenerative diseases. IARC Sci Publ 163:407\u2013419","journal-title":"IARC Sci Publ"},{"issue":"4","key":"4143_CR3","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","volume":"186","author":"DM Wilson","year":"2023","unstructured":"Wilson DM, Cookson MR, Van Den Bosch L, Zetterberg H, Holtzman DM, Dewachter I (2023) Hallmarks of neurodegenerative diseases. Cell. 186(4):693\u2013714","journal-title":"Cell."},{"issue":"10","key":"4143_CR4","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/s41593-018-0237-7","volume":"21","author":"L Gan","year":"2018","unstructured":"Gan L, Cookson MR, Petrucelli L, La Spada AR (2018) Converging pathways in neurodegeneration, from genetics to mechanisms. Nat Neurosci 21(10):1300\u20131309","journal-title":"Nat Neurosci"},{"key":"4143_CR5","volume-title":"Disclosure: Jack Tsao declares no relevant financial relationships with ineligible companies.: StatPearls Publishing Copyright \u00a9 2023","author":"A Kumar","year":"2023","unstructured":"Kumar A, Sidhu J, Goyal A, Tsao JW (2023) Alzheimer Disease. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Jaskirat Sidhu declares no relevant financial relationships with ineligible companies. Disclosure: Amandeep Goyal declares no relevant financial relationships with ineligible companies. In: Disclosure: Jack Tsao declares no relevant financial relationships with ineligible companies.: StatPearls Publishing Copyright \u00a9 2023. StatPearls Publishing LLC"},{"issue":"1","key":"4143_CR6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12929-019-0524-y","volume":"26","author":"MVF Silva","year":"2019","unstructured":"Silva MVF, Loures CMG, Alves LCV, de Souza LC, Borges KBG, Carvalho MG (2019) Alzheimer\u2019s disease: risk factors and potentially protective measures. J Biomed Sci 26(1):33","journal-title":"J Biomed Sci"},{"issue":"8","key":"4143_CR7","first-page":"504","volume":"40","author":"G DeMaagd","year":"2015","unstructured":"DeMaagd G, Philip A (2015) Parkinson's disease and its management: part 1: disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis. P & T : a Peer-Rev J Formula Manag 40(8):504\u2013532","journal-title":"P & T : a Peer-Rev J Formula Manag"},{"issue":"1","key":"4143_CR8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ene.13413","volume":"25","author":"P McColgan","year":"2018","unstructured":"McColgan P, Tabrizi SJ (2018) Huntington's disease: a clinical review. Eur J Neurol 25(1):24\u201334","journal-title":"Eur J Neurol"},{"issue":"1","key":"4143_CR9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1750-1172-5-40","volume":"5","author":"RAC Roos","year":"2010","unstructured":"Roos RAC (2010) Huntington's disease: a clinical review. Orphanet J Rare Dis 5(1):40","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"4143_CR10","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1111\/ene.14393","volume":"27","author":"P Masrori","year":"2020","unstructured":"Masrori P, Van Damme P (2020) Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol 27(10):1918\u20131929","journal-title":"Eur J Neurol"},{"issue":"10","key":"4143_CR11","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41582-019-0244-7","volume":"15","author":"Y Hou","year":"2019","unstructured":"Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL et al (2019) Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol 15(10):565\u2013581","journal-title":"Nat Rev Neurol"},{"key":"4143_CR12","doi-asserted-by":"crossref","first-page":"566767","DOI":"10.3389\/fbioe.2020.566767","volume":"8","author":"M Cascione","year":"2020","unstructured":"Cascione M, De Matteis V, Leporatti S, Rinaldi R (2020) The new frontiers in neurodegenerative diseases treatment: liposomal-based strategies. Front Bioeng Biotechnol 8:566767","journal-title":"Front Bioeng Biotechnol"},{"issue":"1","key":"4143_CR13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1602\/neurorx.1.1.101","volume":"1","author":"SA Lipton","year":"2004","unstructured":"Lipton SA (2004) Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRX 1(1):101\u2013110","journal-title":"NeuroRX"},{"issue":"2","key":"4143_CR14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pharmthera.2004.04.001","volume":"102","author":"PJ Hallett","year":"2004","unstructured":"Hallett PJ, Standaert DG (2004) Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol Ther 102(2):155\u2013174","journal-title":"Pharmacol Ther"},{"key":"4143_CR15","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/B978-0-12-815946-0.00026-0","volume-title":"Diagnosis and Management in Parkinson's Disease","author":"D Luo","year":"2020","unstructured":"Luo D, Reith M, Dutta AK (2020) Chapter 26 - dopamine agonists in treatment of Parkinson's disease: an overview. In: Martin CR, Preedy VR (eds) Diagnosis and Management in Parkinson's Disease. Academic Press, pp. 445\u2013460"},{"issue":"6","key":"4143_CR16","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong MJ, Okun MS (2020) Diagnosis and treatment of Parkinson disease: a review. Jama 323(6):548\u2013560","journal-title":"Jama"},{"key":"4143_CR17","doi-asserted-by":"publisher","unstructured":"Caraci F, Santagati M, Caruso G, Cannav\u00f2 D, Leggio GM, Salomone S et al (2020) New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin. F1000Res 9. https:\/\/doi.org\/10.12688\/f1000research.22662.1","DOI":"10.12688\/f1000research.22662.1"},{"issue":"1","key":"4143_CR18","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40035-022-00292-3","volume":"11","author":"C Song","year":"2022","unstructured":"Song C, Shi J, Zhang P, Zhang Y, Xu J, Zhao L et al (2022) Immunotherapy for Alzheimer's disease: targeting \u03b2-amyloid and beyond. Transl Neurodegen 11(1):18","journal-title":"Transl Neurodegen"},{"issue":"1","key":"4143_CR19","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s13311-018-00694-0","volume":"16","author":"V Sudhakar","year":"2019","unstructured":"Sudhakar V, Richardson RM (2019) Gene therapy for neurodegenerative diseases. Neurotherapeutics 16(1):166\u2013175","journal-title":"Neurotherapeutics"},{"issue":"3","key":"4143_CR20","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.3390\/ijms23031851","volume":"23","author":"RNL Lamptey","year":"2022","unstructured":"Lamptey RNL, Chaulagain B, Trivedi R, Gothwal A, Layek B, Singh J (2022) A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics. Int J Mol Sci 23(3):1851","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4143_CR21","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/tox.23068","volume":"36","author":"SM Afzal","year":"2021","unstructured":"Afzal SM, Vafa A, Rashid S, Barnwal P, Shahid A, Shree A et al (2021) Protective effect of hesperidin against N, N\u2032-dimethylhydrazine induced oxidative stress, inflammation, and apoptotic response in the colon of Wistar rats. Environ Toxicol 36(4):642\u2013653","journal-title":"Environ Toxicol"},{"issue":"24","key":"4143_CR22","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.3390\/molecules25245789","volume":"25","author":"Z Breijyeh","year":"2020","unstructured":"Breijyeh Z, Karaman R (2020) Comprehensive review on Alzheimer\u2019s disease: causes and treatment. Molecules 25(24):5789","journal-title":"Molecules"},{"key":"4143_CR23","doi-asserted-by":"crossref","unstructured":"Czapiewski S, Brown-Nyseth V (2016) Syndromes of brain dysfunction presenting with cognitive impairment or behavioral disturbance: delirium, dementia, and mental disorders due to another medical condition. The Med Basis Psychiatr:17\u201341","DOI":"10.1007\/978-1-4939-2528-5_2"},{"issue":"10248","key":"4143_CR24","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","volume":"396","author":"G Livingston","year":"2020","unstructured":"Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S et al (2020) Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 396(10248):413\u2013446","journal-title":"Lancet"},{"issue":"1","key":"4143_CR25","doi-asserted-by":"crossref","first-page":"a006189","DOI":"10.1101\/cshperspect.a006189","volume":"1","author":"A Serrano-Pozo","year":"2011","unstructured":"Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1(1):a006189","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"7","key":"4143_CR26","first-page":"892","volume":"44","author":"M Khanahmadi","year":"2015","unstructured":"Khanahmadi M, Farhud DD, Malmir M (2015) Genetic of Alzheimer\u2019s disease: a narrative review article. Iran J Public Health 44(7):892","journal-title":"Iran J Public Health"},{"issue":"12","key":"4143_CR27","doi-asserted-by":"crossref","first-page":"e0167201","DOI":"10.1371\/journal.pone.0167201","volume":"11","author":"K-x Wen","year":"2016","unstructured":"Wen K-x, Milic J, El-Khodor B, Dhana K, Nano J, Pulido T et al (2016) The role of DNA methylation and histone modifications in neurodegenerative diseases: a systematic review. Plos One 11(12):e0167201","journal-title":"Plos One"},{"key":"4143_CR28","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.arr.2015.08.001","volume":"24","author":"L Zhao","year":"2015","unstructured":"Zhao L, Woody SK, Chhibber A (2015) Estrogen receptor \u03b2 in Alzheimer\u2019s disease: from mechanisms to therapeutics. Ageing Res Rev 24:178\u2013190","journal-title":"Ageing Res Rev"},{"key":"4143_CR29","doi-asserted-by":"publisher","unstructured":"Hu N, Yu J-T, Tan L, Wang Y-L, Sun L, Tan L (2013) Nutrition and the risk of Alzheimer's disease. Biomed Res Int 2013. https:\/\/doi.org\/10.1155\/2013\/524820","DOI":"10.1155\/2013\/524820"},{"issue":"2-3","key":"4143_CR30","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/JAD-2006-102-303","volume":"10","author":"PA Adlard","year":"2006","unstructured":"Adlard PA, Bush AI (2006) Metals and Alzheimer's disease. J Alzheimers Dis 10(2-3):145\u2013163","journal-title":"J Alzheimers Dis"},{"key":"4143_CR31","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.neubiorev.2016.03.005","volume":"64","author":"D Baglietto-Vargas","year":"2016","unstructured":"Baglietto-Vargas D, Shi J, Yaeger DM, Ager R, LaFerla FM (2016) Diabetes and Alzheimer\u2019s disease crosstalk. Neurosci Biobehav Rev 64:272\u2013287","journal-title":"Neurosci Biobehav Rev"},{"issue":"3","key":"4143_CR32","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3233\/JAD-2010-091561","volume":"20","author":"TC de Toledo Ferraz Alves","year":"2010","unstructured":"de Toledo Ferraz Alves TC, Ferreira LK, Wajngarten M, Busatto GF (2010) Cardiac disorders as risk factors for Alzheimer's disease. J Alzheimers Dis 20(3):749\u2013763","journal-title":"J Alzheimers Dis"},{"key":"4143_CR33","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3389\/fneur.2020.00496","volume":"11","author":"RS Turner","year":"2020","unstructured":"Turner RS, Stubbs T, Davies DA, Albensi BC (2020) Potential new approaches for diagnosis of Alzheimer's disease and related dementias. Front Neurol 11:496","journal-title":"Front Neurol"},{"issue":"6","key":"4143_CR34","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/joim.12816","volume":"284","author":"K Blennow","year":"2018","unstructured":"Blennow K, Zetterberg H (2018) Biomarkers for Alzheimer's disease: current status and prospects for the future. J Intern Med 284(6):643\u2013663","journal-title":"J Intern Med"},{"key":"4143_CR35","doi-asserted-by":"crossref","first-page":"173554","DOI":"10.1016\/j.ejphar.2020.173554","volume":"887","author":"M Vaz","year":"2020","unstructured":"Vaz M, Silvestre S (2020) Alzheimer's disease: recent treatment strategies. Eur J Pharmacol 887:173554","journal-title":"Eur J Pharmacol"},{"issue":"9","key":"4143_CR36","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3390\/pharmaceutics12090801","volume":"12","author":"AS Hanafy","year":"2020","unstructured":"Hanafy AS, Schoch S, Lamprecht A (2020) CRISPR\/CAS9 delivery potentials in Alzheimer\u2019s disease management: a mini review. Pharmaceutics 12(9):801","journal-title":"Pharmaceutics"},{"issue":"18","key":"4143_CR37","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","volume":"378","author":"MF Egan","year":"2018","unstructured":"Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B et al (2018) Randomized trial of verubecestat for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med 378(18):1691\u20131703","journal-title":"N Engl J Med"},{"issue":"15","key":"4143_CR38","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","volume":"380","author":"MF Egan","year":"2019","unstructured":"Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL et al (2019) Randomized trial of verubecestat for prodromal Alzheimer\u2019s disease. N Engl J Med 380(15):1408\u20131420","journal-title":"N Engl J Med"},{"key":"4143_CR39","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.trci.2018.03.009","volume":"4","author":"J Cummings","year":"2018","unstructured":"Cummings J, Lee G, Ritter A, Zhong K (2018) Alzheimer's disease drug development pipeline: 2018. Alzheimer's & Dementia 4:195\u2013214","journal-title":"Alzheimer's & Dementia"},{"issue":"23","key":"4143_CR40","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1001\/jama.2009.1866","volume":"302","author":"RC Green","year":"2009","unstructured":"Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA et al (2009) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. Jama 302(23):2557\u20132564","journal-title":"Jama"},{"issue":"11","key":"4143_CR41","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1001\/jamaneurol.2015.0607","volume":"72","author":"V Coric","year":"2015","unstructured":"Coric V, Salloway S, van Dyck CH, Dubois B, Andreasen N, Brody M et al (2015) Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial. JAMA Neurol 72(11):1324\u20131333","journal-title":"JAMA Neurol"},{"key":"4143_CR42","doi-asserted-by":"publisher","unstructured":"Sampson EL, Jenagaratnam L, McShane R (2014) Metal protein attenuating compounds for the treatment of Alzheimer's dementia. Cochrane Database Syst Rev 2. https:\/\/doi.org\/10.1002\/14651858.CD005380.pub5","DOI":"10.1002\/14651858.CD005380.pub5"},{"issue":"12","key":"4143_CR43","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1001\/archneur.60.12.1685","volume":"60","author":"CW Ritchie","year":"2003","unstructured":"Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L et al (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting A\u03b2 amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 60(12):1685\u20131691","journal-title":"Arch Neurol"},{"issue":"9","key":"4143_CR44","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1474-4422(08)70167-4","volume":"7","author":"L Lannfelt","year":"2008","unstructured":"Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J et al (2008) Safety, efficacy, and biomarker findings of PBT2 in targeting A\u03b2 as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. The Lancet Neurol 7(9):779\u2013786","journal-title":"The Lancet Neurol"},{"key":"4143_CR45","doi-asserted-by":"crossref","first-page":"619667","DOI":"10.3389\/fnins.2020.619667","volume":"14","author":"K Pagano","year":"2020","unstructured":"Pagano K, Tomaselli S, Molinari H, Ragona L (2020) Natural compounds as inhibitors of A\u03b2 peptide aggregation: chemical requirements and molecular mechanisms. Front Neurosci 14:619667","journal-title":"Front Neurosci"},{"issue":"12","key":"4143_CR46","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3390\/biology9120425","volume":"9","author":"F Mantile","year":"2020","unstructured":"Mantile F, Prisco A (2020) Vaccination against \u03b2-amyloid as a strategy for the prevention of Alzheimer\u2019s disease. Biology 9(12):425","journal-title":"Biology"},{"issue":"4","key":"4143_CR47","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/iub.1262","volume":"66","author":"R Pillai","year":"2014","unstructured":"Pillai R, Uyehara-Lock JH, Bellinger FP (2014) Selenium and selenoprotein function in brain disorders. IUBMB Life 66(4):229\u2013239","journal-title":"IUBMB Life"},{"key":"4143_CR48","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jbiotec.2015.02.032","volume":"202","author":"HS Khalil","year":"2015","unstructured":"Khalil HS, Mitev V, Vlaykova T, Cavicchi L, Zhelev N (2015) Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance. J Biotechnol 202:40\u201349","journal-title":"J Biotechnol"},{"key":"4143_CR49","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.phrs.2016.02.007","volume":"106","author":"GM Leggio","year":"2016","unstructured":"Leggio GM, Catania MV, Puzzo D, Spatuzza M, Pellitteri R, Gulisano W et al (2016) The antineoplastic drug flavopiridol reverses memory impairment induced by amyloid-\u00df1-42 oligomers in mice. Pharmacol Res 106:10\u201320","journal-title":"Pharmacol Res"},{"issue":"1","key":"4143_CR50","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/JAD-141959","volume":"45","author":"S Lovestone","year":"2015","unstructured":"Lovestone S, Boada M, Dubois B, H\u00fcll M, Rinne JO, Huppertz H-J et al (2015) A phase II trial of tideglusib in Alzheimer's disease. J Alzheimers Dis 45(1):75\u201388","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"4143_CR51","first-page":"104","volume":"10","author":"M Andrade Nunes","year":"2013","unstructured":"Andrade Nunes M, Araujo Viel T, Sousa BH (2013) Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease. Curr Alzheimer Res 10(1):104\u2013107","journal-title":"Curr Alzheimer Res"},{"issue":"4","key":"4143_CR52","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3233\/JAD-190256","volume":"69","author":"S Matsunaga","year":"2019","unstructured":"Matsunaga S, Fujishiro H, Takechi H (2019) Efficacy and safety of glycogen synthase kinase 3 inhibitors for Alzheimer\u2019s disease: a systematic review and meta-analysis. J Alzheimers Dis 69(4):1031\u20131039","journal-title":"J Alzheimers Dis"},{"issue":"15","key":"4143_CR53","doi-asserted-by":"crossref","first-page":"8208","DOI":"10.3390\/ijms22158208","volume":"22","author":"T-W Yu","year":"2021","unstructured":"Yu T-W, Lane H-Y, Lin C-H (2021) Novel therapeutic approaches for Alzheimer\u2019s disease: an updated review. Int J Mol Sci 22(15):8208","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4143_CR54","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3233\/JAD-142874","volume":"44","author":"CM Wischik","year":"2015","unstructured":"Wischik CM, Staff RT, Wischik DJ, Bentham P, Murray AD, Storey J et al (2015) Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease. J Alzheimers Dis 44(2):705\u2013720","journal-title":"J Alzheimers Dis"},{"issue":"10062","key":"4143_CR55","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","volume":"388","author":"S Gauthier","year":"2016","unstructured":"Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH et al (2016) Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet 388(10062):2873\u20132884","journal-title":"Lancet"},{"issue":"5","key":"4143_CR56","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1177\/0269881114552744","volume":"29","author":"KH Cox","year":"2015","unstructured":"Cox KH, Pipingas A, Scholey AB (2015) Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population. J Psychopharmacol 29(5):642\u2013651","journal-title":"J Psychopharmacol"},{"issue":"31","key":"4143_CR57","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.2174\/138161211798072553","volume":"17","author":"I Gozes","year":"2011","unstructured":"Gozes I (2011) Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des 17(31):3413\u20133417","journal-title":"Curr Pharm Des"},{"issue":"5","key":"4143_CR58","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1586\/17512433.2013.827403","volume":"6","author":"BH Morimoto","year":"2013","unstructured":"Morimoto BH, Fox AW, Stewart AJ, Gold M (2013) Davunetide: a review of safety and efficacy data with a focus on neurodegenerative diseases. Expert Rev Clin Pharmacol 6(5):483\u2013502","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"11","key":"4143_CR59","first-page":"2325","volume":"55","author":"DM Bollag","year":"1995","unstructured":"Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J et al (1995) Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55(11):2325\u20132333","journal-title":"Cancer Res"},{"issue":"9","key":"4143_CR60","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1158\/1535-7163.MCT-12-0061","volume":"11","author":"DP Fitzgerald","year":"2012","unstructured":"Fitzgerald DP, Emerson DL, Qian Y, Anwar T, Liewehr DJ, Steinberg SM et al (2012) TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells. Mol Cancer Ther 11(9):1959\u20131967","journal-title":"Mol Cancer Ther"},{"key":"4143_CR61","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s11060-018-2755-2","volume":"137","author":"CT Zumbar","year":"2018","unstructured":"Zumbar CT, Usubalieva A, King PD, Li X, Mifsud CS, Dalton HM et al (2018) The CNS penetrating taxane TPI 287 and the AURKA inhibitor alisertib induce synergistic apoptosis in glioblastoma cells. J Neuro-Oncol 137:481\u2013492","journal-title":"J Neuro-Oncol"},{"issue":"10","key":"4143_CR62","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.2174\/138161211795589373","volume":"17","author":"I Gozes","year":"2011","unstructured":"Gozes I (2011) NAP (davunetide) provides functional and structural neuroprotection. Curr Pharm Des 17(10):1040\u20131044","journal-title":"Curr Pharm Des"},{"issue":"9","key":"4143_CR63","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2217\/imt-2016-0019","volume":"8","author":"F Panza","year":"2016","unstructured":"Panza F, Solfrizzi V, Seripa D, Imbimbo BP, Lozupone M, Santamato A et al (2016) Tau-based therapeutics for Alzheimer\u2019s disease: active and passive immunotherapy. Immunotherapy 8(9):1119\u20131134","journal-title":"Immunotherapy"},{"key":"4143_CR64","first-page":"63","volume":"6","author":"P Novak","year":"2019","unstructured":"Novak P, Zilka N, Zilkova M, Kovacech B, Skrabana R, Ondrus M et al (2019) AADvac1, an active immunotherapy for Alzheimer\u2019s disease and non Alzheimer tauopathies: an overview of preclinical and clinical development. J Prev Alzheimers Dis 6:63\u201369","journal-title":"J Prev Alzheimers Dis"},{"issue":"8","key":"4143_CR65","doi-asserted-by":"crossref","first-page":"e72301","DOI":"10.1371\/journal.pone.0072301","volume":"8","author":"C Theunis","year":"2013","unstructured":"Theunis C, Crespo-Biel N, Gafner V, Pihlgren M, L\u00f3pez-Deber MP, Reis P et al (2013) Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau. P301L mice that model tauopathy. PloS one 8(8):e72301","journal-title":"PloS one"},{"issue":"6","key":"4143_CR66","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/13543784.2019.1619694","volume":"28","author":"JL Hoskin","year":"2019","unstructured":"Hoskin JL, Sabbagh MN, Al-Hasan Y, Decourt B (2019) Tau immunotherapies for Alzheimer\u2019s disease. Expert Opin Investig Drugs 28(6):545\u2013554","journal-title":"Expert Opin Investig Drugs"},{"key":"4143_CR67","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.trci.2018.10.007","volume":"4","author":"IA Qureshi","year":"2018","unstructured":"Qureshi IA, Tirucherai G, Ahlijanian MK, Kolaitis G, Bechtold C, Grundman M (2018) A randomized, single ascending dose study of intravenous BIIB092 in healthy participants. Alzheimer's & Dementia 4:746\u2013755","journal-title":"Alzheimer's & Dementia"},{"key":"4143_CR68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-017-0233-5","volume":"13","author":"J Cao","year":"2018","unstructured":"Cao J, Hou J, Ping J, Cai D (2018) Advances in developing novel therapeutic strategies for Alzheimer\u2019s disease. Mol Neurodegener 13:1\u201320","journal-title":"Mol Neurodegener"},{"issue":"3","key":"4143_CR69","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.3233\/JAD-160467","volume":"54","author":"A Boehm-Cagan","year":"2016","unstructured":"Boehm-Cagan A, Bar R, Liraz O, Bielicki JK, Johansson JO, Michaelson DM (2016) ABCA1 agonist reverses the ApoE4-driven cognitive and brain pathologies. J Alzheimers Dis 54(3):1219\u20131233","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"4143_CR70","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.expneurol.2011.11.036","volume":"233","author":"DB Santos","year":"2012","unstructured":"Santos DB, Peres KC, Ribeiro RP, Colle D, dos Santos AA, Moreira EL et al (2012) Probucol, a lipid-lowering drug, prevents cognitive and hippocampal synaptic impairments induced by amyloid \u03b2 peptide in mice. Exp Neurol 233(2):767\u2013775","journal-title":"Exp Neurol"},{"key":"4143_CR71","doi-asserted-by":"crossref","first-page":"146685","DOI":"10.1016\/j.brainres.2020.146685","volume":"1733","author":"K Krishnamurthy","year":"2020","unstructured":"Krishnamurthy K, Cantillana V, Wang H, Sullivan PM, Kolls BJ, Ge X et al (2020) ApoE mimetic improves pathology and memory in a model of Alzheimer\u2019s disease. Brain Res 1733:146685","journal-title":"Brain Res"},{"issue":"1","key":"4143_CR72","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S1474-4422(20)30412-9","volume":"20","author":"A Serrano-Pozo","year":"2021","unstructured":"Serrano-Pozo A, Das S, Hyman BT (2021) APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches. The Lancet Neurology 20(1):68\u201380","journal-title":"The Lancet Neurology"},{"issue":"1","key":"4143_CR73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JAD-201027","volume":"81","author":"A Miranda","year":"2021","unstructured":"Miranda A, Montiel E, Ulrich H, Paz C (2021) Selective secretase targeting for Alzheimer\u2019s disease therapy. J Alzheimers Dis 81(1):1\u201317","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"4143_CR74","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/14737175.2019.1621751","volume":"19","author":"F Panza","year":"2019","unstructured":"Panza F, Lozupone M, Watling M, Imbimbo BP (2019) Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease? Expert Rev Neurother 19(7):599\u2013602","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"4143_CR75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","volume":"27","author":"L-K Huang","year":"2020","unstructured":"Huang L-K, Chao S-P, Hu C-J (2020) Clinical trials of new drugs for Alzheimer disease. J Biomed Sci 27(1):1\u201313","journal-title":"J Biomed Sci"},{"key":"4143_CR76","doi-asserted-by":"crossref","first-page":"138313","DOI":"10.1016\/j.scitotenv.2020.138313","volume":"725","author":"MS Uddin","year":"2020","unstructured":"Uddin MS, Hossain MF, Al Mamun A, Shah MA, Hasana S, Bulbul IJ et al (2020) Exploring the multimodal role of phytochemicals in the modulation of cellular signaling pathways to combat age-related neurodegeneration. Sci Total Environ 725:138313","journal-title":"Sci Total Environ"},{"key":"4143_CR77","volume-title":"Three FDA advisory panel members resign over approval of Alzheimer\u2019s drug","author":"E Mahase","year":"2021","unstructured":"Mahase E (2021) Three FDA advisory panel members resign over approval of Alzheimer\u2019s drug. British Medical Journal Publishing Group"},{"key":"4143_CR78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-020-00663-w","volume":"12","author":"M Tolar","year":"2020","unstructured":"Tolar M, Abushakra S, Hey JA, Porsteinsson A, Sabbagh M (2020) Aducanumab, gantenerumab, BAN2401, and ALZ-801\u2014the first wave of amyloid-targeting drugs for Alzheimer\u2019s disease with potential for near term approval. Alzheimers Res Ther 12:1\u201310","journal-title":"Alzheimers Res Ther"},{"issue":"10","key":"4143_CR79","doi-asserted-by":"crossref","first-page":"a006296","DOI":"10.1101\/cshperspect.a006296","volume":"2","author":"RE Tanzi","year":"2012","unstructured":"Tanzi RE (2012) The genetics of Alzheimer disease. Cold Spring Harb Perspect Med 2(10):a006296","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"2","key":"4143_CR80","first-page":"671","volume":"118","author":"SE Wahrle","year":"2008","unstructured":"Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A et al (2008) Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest 118(2):671\u2013682","journal-title":"J Clin Invest"},{"issue":"52","key":"4143_CR81","doi-asserted-by":"crossref","first-page":"43236","DOI":"10.1074\/jbc.M508780200","volume":"280","author":"SE Wahrle","year":"2005","unstructured":"Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM et al (2005) Deletion of Abca1 increases A\u03b2 deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem 280(52):43236\u201343242","journal-title":"J Biol Chem"},{"issue":"1","key":"4143_CR82","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0306-4522(03)00361-0","volume":"121","author":"D Champagne","year":"2003","unstructured":"Champagne D, Pearson D, Dea D, Rochford J, Poirier J (2003) The cholesterol-lowering drug probucol increases apolipoprotein E production in the hippocampus of aged rats: implications for Alzheimer\u2019s disease. Neuroscience 121(1):99\u2013110","journal-title":"Neuroscience"},{"issue":"5","key":"4143_CR83","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.ajpath.2013.01.034","volume":"182","author":"MA Kuszczyk","year":"2013","unstructured":"Kuszczyk MA, Sanchez S, Pankiewicz J, Kim J, Duszczyk M, Guridi M et al (2013) Blocking the interaction between apolipoprotein E and A\u03b2 reduces intraneuronal accumulation of A\u03b2 and inhibits synaptic degeneration. Am J Pathol 182(5):1750\u20131768","journal-title":"Am J Pathol"},{"issue":"6","key":"4143_CR84","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/1531-8249(200006)47:6<739::AID-ANA6>3.0.CO;2-8","volume":"47","author":"DM Holtzman","year":"2000","unstructured":"Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, Paul SM et al (2000) Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol 47(6):739\u2013747","journal-title":"Ann Neurol"},{"issue":"4","key":"4143_CR85","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1084\/jem.20171265","volume":"215","author":"JD Ulrich","year":"2018","unstructured":"Ulrich JD, Ulland TK, Mahan TE, Nystr\u00f6m S, Nilsson KP, Song WM et al (2018) ApoE facilitates the microglial response to amyloid plaque pathology. J Exp Med 215(4):1047\u20131058","journal-title":"J Exp Med"},{"issue":"5","key":"4143_CR86","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.neuron.2009.11.013","volume":"64","author":"J Kim","year":"2009","unstructured":"Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V et al (2009) Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A\u03b2 clearance. Neuron 64(5):632\u2013644","journal-title":"Neuron"},{"issue":"5","key":"4143_CR87","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.neuron.2017.11.014","volume":"96","author":"T-PV Huynh","year":"2017","unstructured":"Huynh T-PV, Liao F, Francis CM, Robinson GO, Serrano JR, Jiang H et al (2017) Age-dependent effects of apoE reduction using antisense oligonucleotides in a model of \u03b2-amyloidosis. Neuron 96(5):1013\u201323. e4","journal-title":"Neuron"},{"issue":"6","key":"4143_CR88","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.neuron.2018.05.008","volume":"98","author":"Y-T Lin","year":"2018","unstructured":"Lin Y-T, Seo J, Gao F, Feldman HM, Wen H-L, Penney J et al (2018) APOE4 causes widespread molecular and cellular alterations associated with Alzheimer\u2019s disease phenotypes in human iPSC-derived brain cell types. Neuron 98(6):1141\u201354.e7","journal-title":"Neuron"},{"issue":"212","key":"4143_CR89","doi-asserted-by":"crossref","first-page":"212ra161","DOI":"10.1126\/scitranslmed.3007000","volume":"5","author":"E Hudry","year":"2013","unstructured":"Hudry E, Dashkoff J, Roe AD, Takeda S, Koffie RM, Hashimoto T et al (2013) Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Sci Transl Med 5(212):212ra161","journal-title":"Sci Transl Med"},{"key":"4143_CR90","doi-asserted-by":"crossref","first-page":"590896","DOI":"10.3389\/fnmol.2020.590896","volume":"13","author":"Y Soeda","year":"2020","unstructured":"Soeda Y, Takashima A (2020) New insights into drug discovery targeting tau protein. Front Mol Neurosci 13:590896","journal-title":"Front Mol Neurosci"},{"issue":"5","key":"4143_CR91","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jmb.2015.10.014","volume":"428","author":"S Chandrasegaran","year":"2016","unstructured":"Chandrasegaran S, Carroll D (2016) Origins of programmable nucleases for genome engineering. J Mol Biol 428(5):963\u2013989","journal-title":"J Mol Biol"},{"issue":"6213","key":"4143_CR92","doi-asserted-by":"crossref","first-page":"1258096","DOI":"10.1126\/science.1258096","volume":"346","author":"JA Doudna","year":"2014","unstructured":"Doudna JA, Charpentier E (2014) The new frontier of genome engineering with CRISPR-Cas9. Science 346(6213):1258096","journal-title":"Science"},{"issue":"1","key":"4143_CR93","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.chembiol.2015.12.009","volume":"23","author":"JH Hu","year":"2016","unstructured":"Hu JH, Davis KM, Liu DR (2016) Chemical biology approaches to genome editing: understanding, controlling, and delivering programmable nucleases. Cell Chem Biol 23(1):57\u201373","journal-title":"Cell Chem Biol"},{"issue":"6","key":"4143_CR94","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","volume":"157","author":"PD Hsu","year":"2014","unstructured":"Hsu PD, Lander ES, Zhang F (2014) Development and applications of CRISPR-Cas9 for genome engineering. Cell 157(6):1262\u20131278","journal-title":"Cell"},{"issue":"6121","key":"4143_CR95","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","volume":"339","author":"L Cong","year":"2013","unstructured":"Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N et al (2013) Multiplex genome engineering using CRISPR\/Cas systems. Science 339(6121):819\u2013823","journal-title":"Science"},{"issue":"6","key":"4143_CR96","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nbt.2884","volume":"32","author":"H Yin","year":"2014","unstructured":"Yin H, Xue W, Chen S, Bogorad RL, Benedetti E, Grompe M et al (2014) Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol 32(6):551\u2013553","journal-title":"Nat Biotechnol"},{"issue":"5","key":"4143_CR97","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s13238-015-0153-5","volume":"6","author":"P Liang","year":"2015","unstructured":"Liang P, Xu Y, Zhang X, Ding C, Huang R, Zhang Z et al (2015) CRISPR\/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell 6(5):363\u2013372","journal-title":"Protein Cell"},{"issue":"6","key":"4143_CR98","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.stem.2013.11.002","volume":"13","author":"G Schwank","year":"2013","unstructured":"Schwank G, Koo B-K, Sasselli V, Dekkers JF, Heo I, Demircan T et al (2013) Functional repair of CFTR by CRISPR\/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell 13(6):653\u2013658","journal-title":"Cell Stem Cell"},{"issue":"6271","key":"4143_CR99","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.aad5177","volume":"351","author":"M Tabebordbar","year":"2016","unstructured":"Tabebordbar M, Zhu K, Cheng JK, Chew WL, Widrick JJ, Yan WX et al (2016) In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 351(6271):407\u2013411","journal-title":"Science"},{"issue":"6271","key":"4143_CR100","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.aad5143","volume":"351","author":"CE Nelson","year":"2016","unstructured":"Nelson CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, Rivera RMC et al (2016) In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 351(6271):403\u2013407","journal-title":"Science"},{"issue":"6201","key":"4143_CR101","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1126\/science.1254445","volume":"345","author":"C Long","year":"2014","unstructured":"Long C, McAnally JR, Shelton JM, Mireault AA, Bassel-Duby R, Olson EN (2014) Prevention of muscular dystrophy in mice by CRISPR\/Cas9\u2013mediated editing of germline DNA. Science 345(6201):1184\u20131188","journal-title":"Science"},{"issue":"1","key":"4143_CR102","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ajhg.2015.11.012","volume":"98","author":"D Wojtal","year":"2016","unstructured":"Wojtal D, Kemaladewi DU, Malam Z, Abdullah S, Wong TW, Hyatt E et al (2016) Spell checking nature: versatility of CRISPR\/Cas9 for developing treatments for inherited disorders. Am J Hum Genet 98(1):90\u2013101","journal-title":"Am J Hum Genet"},{"issue":"7577","key":"4143_CR103","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nature15521","volume":"527","author":"MC Canver","year":"2015","unstructured":"Canver MC, Smith EC, Sher F, Pinello L, Sanjana NE, Shalem O et al (2015) BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature 527(7577):192\u2013197","journal-title":"Nature"},{"issue":"5","key":"4143_CR104","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.jcyt.2019.04.022","volume":"21","author":"R Rabinowitz","year":"2019","unstructured":"Rabinowitz R, Kadair A, Ben-Zur T, Michaelson D, Offen D (2019) ApoE4 allele specific knockout using a synthetic Cas9 variant as a potential gene therapy approach for Alzheimer's disease. Cytotherapy 21(5):e7","journal-title":"Cytotherapy"},{"issue":"2","key":"4143_CR105","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ymthe.2020.09.028","volume":"29","author":"G Sharma","year":"2021","unstructured":"Sharma G, Sharma AR, Bhattacharya M, Lee SS, Chakraborty C (2021) CRISPR-Cas9: a preclinical and clinical perspective for the treatment of human diseases. Mol Ther 29(2):571\u2013586","journal-title":"Mol Ther"},{"issue":"7542","key":"4143_CR106","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nature14245","volume":"519","author":"R Heler","year":"2015","unstructured":"Heler R, Samai P, Modell JW, Weiner C, Goldberg GW, Bikard D et al (2015) Cas9 specifies functional viral targets during CRISPR-Cas adaptation. Nature 519(7542):199\u2013202","journal-title":"Nature"},{"issue":"27","key":"4143_CR107","doi-asserted-by":"crossref","first-page":"9798","DOI":"10.1073\/pnas.1402597111","volume":"111","author":"MD Szczelkun","year":"2014","unstructured":"Szczelkun MD, Tikhomirova MS, Sinkunas T, Gasiunas G, Karvelis T, Pschera P et al (2014) Direct observation of R-loop formation by single RNA-guided Cas9 and cascade effector complexes. Proc Natl Acad Sci USA 111(27):9798\u20139803","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7490","key":"4143_CR108","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nature13011","volume":"507","author":"SH Sternberg","year":"2014","unstructured":"Sternberg SH, Redding S, Jinek M, Greene EC, Doudna JA (2014) DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature 507(7490):62\u201367","journal-title":"Nature"},{"issue":"7340","key":"4143_CR109","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/nature09886","volume":"471","author":"E Deltcheva","year":"2011","unstructured":"Deltcheva E, Chylinski K, Sharma CM, Gonzales K, Chao Y, Pirzada ZA et al (2011) CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 471(7340):602\u2013607","journal-title":"Nature"},{"issue":"39","key":"4143_CR110","doi-asserted-by":"crossref","first-page":"E2579","DOI":"10.1073\/pnas.1208507109","volume":"109","author":"G Gasiunas","year":"2012","unstructured":"Gasiunas G, Barrangou R, Horvath P, Siksnys V (2012) Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci USA 109(39):E2579\u2013E2586","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6096","key":"4143_CR111","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E (2012) A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337(6096):816\u2013821","journal-title":"Science"},{"key":"4143_CR112","doi-asserted-by":"crossref","first-page":"17092","DOI":"10.1038\/nmicrobiol.2017.92","volume":"2","author":"R Barrangou","year":"2017","unstructured":"Barrangou R, Horvath P (2017) A decade of discovery: CRISPR functions and applications. Nat Microbiol 2:17092","journal-title":"Nat Microbiol"},{"issue":"3","key":"4143_CR113","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.cell.2021.01.019","volume":"184","author":"LS Qi","year":"2021","unstructured":"Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP et al (2021) Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 184(3):844","journal-title":"Cell"},{"issue":"1","key":"4143_CR114","doi-asserted-by":"crossref","first-page":"bpy002","DOI":"10.1093\/biomethods\/bpy002","volume":"3","author":"T Anton","year":"2018","unstructured":"Anton T, Karg E, Bultmann S (2018) Applications of the CRISPR\/Cas system beyond gene editing. Biol Methods Protoc 3(1):bpy002","journal-title":"Biol Methods Protoc"},{"issue":"1","key":"4143_CR115","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrn.2015.2","volume":"17","author":"M Heidenreich","year":"2016","unstructured":"Heidenreich M, Zhang F (2016) Applications of CRISPR-Cas systems in neuroscience. Nat Rev Neurosci 17(1):36\u201344","journal-title":"Nat Rev Neurosci"},{"issue":"6","key":"4143_CR116","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.cell.2013.08.021","volume":"154","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konermann S, Trevino AE et al (2013) Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154(6):1380\u20131389","journal-title":"Cell"},{"key":"4143_CR117","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fbioe.2020.00062","volume":"8","author":"Y Zheng","year":"2020","unstructured":"Zheng Y, Li J, Wang B, Han J, Hao Y, Wang S et al (2020) Endogenous type I CRISPR-Cas: from foreign DNA defense to prokaryotic engineering. Front Bioeng Biotechnol 8:62","journal-title":"Front Bioeng Biotechnol"},{"key":"4143_CR118","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s13059-015-0860-5","volume":"16","author":"JA Doudna","year":"2015","unstructured":"Doudna JA, Gersbach CA (2015) Genome editing: the end of the beginning. Genome Biol 16:292","journal-title":"Genome Biol"},{"issue":"2","key":"4143_CR119","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nm.3793","volume":"21","author":"DB Cox","year":"2015","unstructured":"Cox DB, Platt RJ, Zhang F (2015) Therapeutic genome editing: prospects and challenges. Nat Med 21(2):121\u2013131","journal-title":"Nat Med"},{"key":"4143_CR120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jconrel.2017.09.012","volume":"266","author":"C Liu","year":"2017","unstructured":"Liu C, Zhang L, Liu H, Cheng K (2017) Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications. J Control Release 266:17\u201326","journal-title":"J Control Release"},{"issue":"1","key":"4143_CR121","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/mt.2009.255","volume":"18","author":"Z Wu","year":"2010","unstructured":"Wu Z, Yang H, Colosi P (2010) Effect of genome size on AAV vector packaging. Mol Ther 18(1):80\u201386","journal-title":"Mol Ther"},{"issue":"4","key":"4143_CR122","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nbt.2842","volume":"32","author":"JD Sander","year":"2014","unstructured":"Sander JD, Joung JK (2014) CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol 32(4):347\u2013355","journal-title":"Nat Biotechnol"},{"issue":"5","key":"4143_CR123","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/nrg.2016.28","volume":"17","author":"SQ Tsai","year":"2016","unstructured":"Tsai SQ, Joung JK (2016) Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases. Nat Rev Genet 17(5):300\u2013312","journal-title":"Nat Rev Genet"},{"issue":"7","key":"4143_CR124","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nbt.2916","volume":"32","author":"C Kuscu","year":"2014","unstructured":"Kuscu C, Arslan S, Singh R, Thorpe J, Adli M (2014) Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. Nat Biotechnol 32(7):677\u2013683","journal-title":"Nat Biotechnol"},{"issue":"11","key":"4143_CR125","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1038\/mtna.2015.37","volume":"4","author":"XH Zhang","year":"2015","unstructured":"Zhang XH, Tee LY, Wang XG, Huang QS, Yang SH (2015) Off-target effects in CRISPR\/Cas9-mediated genome engineering. Mol Ther Nucleic Acids 4(11):e264","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"4143_CR126","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13059-016-1012-2","volume":"17","author":"M Haeussler","year":"2016","unstructured":"Haeussler M, Sch\u00f6nig K, Eckert H, Eschstruth A, Miann\u00e9 J, Renaud JB et al (2016) Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR. Genome Biol 17(1):148","journal-title":"Genome Biol"},{"issue":"7544","key":"4143_CR127","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/519410a","volume":"519","author":"E Lanphier","year":"2015","unstructured":"Lanphier E, Urnov F, Haecker SE, Werner M, Smolenski J (2015) Don\u2019t edit the human germ line. Nature 519(7544):410\u2013411","journal-title":"Nature"},{"issue":"6271","key":"4143_CR128","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1126\/science.aad6778","volume":"351","author":"R Isasi","year":"2016","unstructured":"Isasi R, Kleiderman E, Knoppers BM (2016) Genetic technology regulation. Editing policy to fit the genome? Science 351(6271):337\u2013339","journal-title":"Science"},{"issue":"15","key":"4143_CR129","doi-asserted-by":"crossref","first-page":"8714","DOI":"10.3390\/ijms23158714","volume":"23","author":"LM De Plano","year":"2022","unstructured":"De Plano LM, Calabrese G, Conoci S, Guglielmino SPP, Oddo S, Caccamo A (2022) Applications of CRISPR-Cas9 in Alzheimer's disease and related disorders. Int J Mol Sci 23(15):8714","journal-title":"Int J Mol Sci"},{"key":"4143_CR130","doi-asserted-by":"crossref","first-page":"803894","DOI":"10.3389\/fnins.2021.803894","volume":"15","author":"L Lu","year":"2021","unstructured":"Lu L, Yu X, Cai Y, Sun M, Yang H (2021) Application of CRISPR\/Cas9 in Alzheimer's disease. Front Neurosci 15:803894","journal-title":"Front Neurosci"},{"issue":"4","key":"4143_CR131","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMra0909142","volume":"362","author":"HW Querfurth","year":"2010","unstructured":"Querfurth HW, LaFerla FM (2010) Alzheimer's disease. N Engl J Med 362(4):329\u2013344","journal-title":"N Engl J Med"},{"key":"4143_CR132","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jare.2021.07.001","volume":"40","author":"S Bhardwaj","year":"2022","unstructured":"Bhardwaj S, Kesari KK, Rachamalla M, Mani S, Ashraf GM, Jha SK et al (2022) CRISPR\/Cas9 gene editing: new hope for Alzheimer's disease therapeutics. J Adv Res 40:207\u2013221","journal-title":"J Adv Res"},{"issue":"1","key":"4143_CR133","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S1474-4422(12)70259-4","volume":"12","author":"K Bettens","year":"2013","unstructured":"Bettens K, Sleegers K, Van Broeckhoven C (2013) Genetic insights in Alzheimer's disease. Lancet Neurol 12(1):92\u2013104","journal-title":"Lancet Neurol"},{"issue":"6","key":"4143_CR134","doi-asserted-by":"crossref","first-page":"a024539","DOI":"10.1101\/cshperspect.a024539","volume":"7","author":"J Tcw","year":"2017","unstructured":"Tcw J, Goate AM (2017) Genetics of beta-amyloid precursor protein in Alzheimer's disease. Cold Spring Harb Perspect Med 7(6):a024539","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"10","key":"4143_CR135","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.3390\/ijms21103413","volume":"21","author":"B Bae","year":"2020","unstructured":"Bae B, Miura P (2020) Emerging roles for 3' UTRs in neurons. Int J Mol Sci 21(10):3413","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4143_CR136","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.trecan.2019.02.011","volume":"5","author":"SL Schuster","year":"2019","unstructured":"Schuster SL, Hsieh AC (2019) The untranslated regions of mRNAs in cancer. Trends Cancer 5(4):245\u2013262","journal-title":"Trends Cancer"},{"issue":"5","key":"4143_CR137","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1042\/BC20080104","volume":"101","author":"S Chatterjee","year":"2009","unstructured":"Chatterjee S, Pal JK (2009) Role of 5'- and 3'-untranslated regions of mRNAs in human diseases. Biol Cell 101(5):251\u2013262","journal-title":"Biol Cell"},{"issue":"18","key":"4143_CR138","doi-asserted-by":"crossref","first-page":"7130","DOI":"10.1073\/pnas.0509695103","volume":"103","author":"V Galvan","year":"2006","unstructured":"Galvan V, Gorostiza OF, Banwait S, Ataie M, Logvinova AV, Sitaraman S et al (2006) Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. Proc Natl Acad Sci USA 103(18):7130\u20137135","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"4143_CR139","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1038\/s41467-018-04238-0","volume":"9","author":"K Nagata","year":"2018","unstructured":"Nagata K, Takahashi M, Matsuba Y, Okuyama-Uchimura F, Sato K, Hashimoto S et al (2018) Generation of App knock-in mice reveals deletion mutations protective against Alzheimer's disease-like pathology. Nat Commun 9(1):1800","journal-title":"Nat Commun"},{"issue":"5","key":"4143_CR140","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ng0892-345","volume":"1","author":"M Mullan","year":"1992","unstructured":"Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B et al (1992) A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet 1(5):345\u2013347","journal-title":"Nat Genet"},{"key":"4143_CR141","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.omtn.2018.03.007","volume":"11","author":"B Gyorgy","year":"2018","unstructured":"Gyorgy B, Loov C, Zaborowski MP, Takeda S, Kleinstiver BP, Commins C et al (2018) CRISPR\/Cas9 mediated disruption of the Swedish APP allele as a therapeutic approach for early-onset Alzheimer's disease. Mol Ther Nucleic Acids 11:429\u2013440","journal-title":"Mol Ther Nucleic Acids"},{"issue":"9","key":"4143_CR142","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/ng.3916","volume":"49","author":"R Sims","year":"2017","unstructured":"Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J et al (2017) Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet 49(9):1373\u20131384","journal-title":"Nat Genet"},{"issue":"1","key":"4143_CR143","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13024-020-00402-7","volume":"15","author":"M Takalo","year":"2020","unstructured":"Takalo M, Wittrahm R, Wefers B, Parhizkar S, Jokivarsi K, Kuulasmaa T et al (2020) The Alzheimer's disease-associated protective Plcgamma2-P522R variant promotes immune functions. Mol Neurodegener 15(1):52","journal-title":"Mol Neurodegener"},{"issue":"3","key":"4143_CR144","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3390\/ijms22031244","volume":"22","author":"A Yang","year":"2021","unstructured":"Yang A, Kantor B, Chiba-Falek O (2021) APOE: the new frontier in the development of a therapeutic target towards precision medicine in late-onset Alzheimer's. Int J Mol Sci 22(3):1244","journal-title":"Int J Mol Sci"},{"issue":"5","key":"4143_CR145","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41591-018-0004-z","volume":"24","author":"C Wang","year":"2018","unstructured":"Wang C, Najm R, Xu Q, Jeong DE, Walker D, Balestra ME et al (2018) Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. Nat Med 24(5):647\u2013657","journal-title":"Nat Med"},{"issue":"2","key":"4143_CR146","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","volume":"9","author":"CC Liu","year":"2013","unstructured":"Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9(2):106\u2013118","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"4143_CR147","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1590\/S0100-879X2011007500151","volume":"45","author":"BV de Almada","year":"2012","unstructured":"de Almada BV, de Almeida LD, Camporez D, de Moraes MV, Morelato RL, Perrone AM et al (2012) Protective effect of the APOE-e3 allele in Alzheimer's disease. Braz J Med Biol Res 45(1):8\u201312","journal-title":"Braz J Med Biol Res"},{"issue":"3","key":"4143_CR148","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3233\/JAD-140033","volume":"42","author":"R Delabio","year":"2014","unstructured":"Delabio R, Rasmussen L, Mizumoto I, Viani GA, Chen E, Villares J et al (2014) PSEN1 and PSEN2 gene expression in Alzheimer's disease brain: a new approach. J Alzheimers Dis 42(3):757\u2013760","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"4143_CR149","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40478-017-0475-z","volume":"5","author":"M Ortiz-Virumbrales","year":"2017","unstructured":"Ortiz-Virumbrales M, Moreno CL, Kruglikov I, Marazuela P, Sproul A, Jacob S et al (2017) CRISPR\/Cas9-Correctable mutation-related molecular and physiological phenotypes in iPSC-derived Alzheimer's PSEN2 (N141I) neurons. Acta Neuropathol Commun 5(1):77","journal-title":"Acta Neuropathol Commun"},{"issue":"3","key":"4143_CR150","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1474-4422(13)70276-X","volume":"13","author":"R Yan","year":"2014","unstructured":"Yan R, Vassar R (2014) Targeting the beta secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol 13(3):319\u2013329","journal-title":"Lancet Neurol"},{"issue":"4","key":"4143_CR151","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41593-019-0352-0","volume":"22","author":"H Park","year":"2019","unstructured":"Park H, Oh J, Shim G, Cho B, Chang Y, Kim S et al (2019) In vivo neuronal gene editing via CRISPR-Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer's disease. Nat Neurosci 22(4):524\u2013528","journal-title":"Nat Neurosci"},{"issue":"7311","key":"4143_CR152","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nature09325","volume":"467","author":"G He","year":"2010","unstructured":"He G, Luo W, Li P, Remmers C, Netzer WJ, Hendrick J et al (2010) Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature 467(7311):95\u201398","journal-title":"Nature"},{"issue":"13","key":"4143_CR153","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.1073\/pnas.1820160116","volume":"116","author":"E Wong","year":"2019","unstructured":"Wong E, Liao GP, Chang JC, Xu P, Li YM, Greengard P (2019) GSAP modulates gamma-secretase specificity by inducing conformational change in PS1. Proc Natl Acad Sci USA 116(13):6385\u20136390","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"4143_CR154","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.3390\/molecules22081287","volume":"22","author":"JK Lee","year":"2017","unstructured":"Lee JK, Kim NJ (2017) Recent advances in the inhibition of p38 MAPK as a potential strategy for the treatment of Alzheimer's disease. Molecules 22(8):1287","journal-title":"Molecules"},{"issue":"1","key":"4143_CR155","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s12035-018-1068-y","volume":"56","author":"SP Raikwar","year":"2019","unstructured":"Raikwar SP, Thangavel R, Dubova I, Selvakumar GP, Ahmed ME, Kempuraj D et al (2019) Targeted gene editing of glia maturation factor in microglia: a novel Alzheimer's disease therapeutic target. Mol Neurobiol 56(1):378\u2013393","journal-title":"Mol Neurobiol"},{"issue":"2","key":"4143_CR156","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40120-020-00218-z","volume":"9","author":"NC Barman","year":"2020","unstructured":"Barman NC, Khan NM, Islam M, Nain Z, Roy RK, Haque A et al (2020) CRISPR-Cas9: a promising genome editing therapeutic tool for Alzheimer's disease-a narrative review. Neurol Ther 9(2):419\u2013434","journal-title":"Neurol Ther"},{"issue":"1","key":"4143_CR157","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41467-018-07971-8","volume":"10","author":"J Sun","year":"2019","unstructured":"Sun J, Carlson-Stevermer J, Das U, Shen M, Delenclos M, Snead AM et al (2019) CRISPR\/Cas9 editing of APP C-terminus attenuates beta-cleavage and promotes alpha-cleavage. Nat Commun 10(1):53","journal-title":"Nat Commun"},{"issue":"12","key":"4143_CR158","doi-asserted-by":"crossref","first-page":"5355","DOI":"10.1073\/pnas.91.12.5355","volume":"91","author":"MF Perutz","year":"1994","unstructured":"Perutz MF, Johnson T, Suzuki M, Finch JT (1994) Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci USA 91(12):5355\u20135358","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7536","key":"4143_CR159","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nature14136","volume":"517","author":"S Konermann","year":"2015","unstructured":"Konermann S, Brigham MD, Trevino AE, Joung J, Abudayyeh OO, Barcena C et al (2015) Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517(7536):583\u2013588","journal-title":"Nature"},{"key":"4143_CR160","doi-asserted-by":"crossref","first-page":"121229","DOI":"10.1016\/j.biomaterials.2021.121229","volume":"279","author":"H Park","year":"2021","unstructured":"Park H, Hwang Y, Kim J (2021) Transcriptional activation with Cas9 activator nanocomplexes rescues Alzheimer's disease pathology. Biomaterials 279:121229","journal-title":"Biomaterials"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-024-04143-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-024-04143-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-024-04143-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T11:09:14Z","timestamp":1729595354000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-024-04143-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,19]]},"references-count":160,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["4143"],"URL":"https:\/\/doi.org\/10.1007\/s12035-024-04143-2","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,19]]},"assertion":[{"value":"17 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is a review and does not need to receive the code of ethics","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}